# US 2026/0034209 A1 · Coronavirus vaccine, production and application

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0034209 A1
- Document ID: US20260034209A1
- Status: Published application
- Kind: A1
- Application number: 19/056,786
- Filed: 2025-02-19
- Published: 2026-02-05
- Earliest claimed: 2024-07-31
- Assignees: Turkiye Bilimsel Ve Teknolojik Arastirma Kurumu
- Applicants: Turkiye Bilimsel Ve Teknolojik Arastirma Kurumu
- Inventors: MERT DOSKAYA; AYTUL GUL; SEDEF ERKUNT ALAK; HUSEYIN CAN; MUHAMMET KARAKAVUK; FATMA GULAY KORUKLUOGLU; AYSU DEGIRMENCI DOSKAYA; HILAL YAZICI MALKOCOGLU; CEREN GUL; TUGBA KARAKAVUK; ERCUMENT KARASULU; ADNAN YUKSEL GURUZ; HIVDA ULBEGI POLAT; CEMAL UN; HASAN AKBABA; AYSE GULTEN KANTARCI; GULSAH EREL AKBABA; HUSNU PULLUKCU; MELTEM TASBAKAN; SABAN TEKIN
- Web page: https://patentgrep.com/patent/US20260034209A1

## CPC

- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61K 39/12: Viral antigens
- A61P 31/14: for RNA viruses
- C07K 14/005: from viruses
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/575: {humoral response}
- C12N 2770/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/20031: Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- C12N 2770/20071: Demonstrated in vivo effect
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

An SARS-COV-2 recombinant Spike protein is provided. The research process of the protein is as follows: the dominant strain in circulation was identified by screening clinical samples of SARS-COV-2 patients and its mutations in Turkey were evaluated by sequencing the Spike gene. Sequencing data and in silico methods were used to design the Spike antigen and then the novel Spike antigen was docked with the human ACE2 (Angiotensin Converting Enzyme-2) receptor to determine the binding energy. After DNA vaccine construction, HEK293T cells were transfected and analyzed for protein expression capacity by IFA, Western blot and RT-qPCR, then BALB/c mice and K18-hACE2 transgenic mice were immunized with DNA vaccine administered intramuscularly (IM) and intradermally (ID) using an electroporator device three times on days 0, 14 and 56. Humoral and cellular immune responses were then analyzed using recombinant ELISA, Western blot, surrogate virus neutralization assay, microneutralization assay, Cytokine ELISA and flow cytometry.

## Claims

### Claim 1

An SARS-COV-2 recombinant Spike protein comprises the amino acid sequence containing a D614G mutation as defined by SEQ ID NO: 1, wherein the SARS-COV-2 recombinant Spike protein is used as a protective vaccine against SARS-COV-2 infection.

### Claim 2 (depends on 1)

The SARS-COV-2 recombinant Spike protein of claim 1, wherein the SARS-COV-2 recombinant Spike protein is a fusion protein comprising an additional polypeptide, wherein the additional polypeptide comprises at least one of a signal peptide, a leader peptide sequence, and a detectable tag.

### Claim 3 (depends on 2)

The SARS-COV-2 recombinant Spike protein of claim 2, wherein the signal peptide is selected from natural signal peptides of IgE.

### Claim 4 (depends on 3)

The SARS-COV-2 recombinant Spike protein of claim 3, wherein the signal peptide is the amino acid sequence defined by SEQ ID NO: 2.

### Claim 5 (depends on 1)

A nucleic acid molecule encoding the SARS-COV-2 recombinant Spike protein of claim 1, wherein the nucleic acid sequence is defined by SEQ ID NO: 3.

### Claim 6 (depends on 1)

A nucleic acid molecule encoding the SARS-COV-2 recombinant Spike protein of claim 1, wherein the nucleic acid molecule comprises a nucleotide sequence encoding a signal peptide defined by SEQ ID NO: 4.

### Claim 7 (depends on 5)

The nucleic acid molecule of claim 5, wherein the nucleic acid sequence is codon optimized or non-codon optimized for a codon preference of a host cell.

### Claim 8 (depends on 7)

The nucleic acid molecule of claim 7, wherein the host cell is a human cell.

### Claim 9 (depends on 5)

A vector comprising the nucleic acid molecule of claim 5, wherein the vector is a plasmid.

### Claim 10 (depends on 9)

The vector of claim 9, wherein the vector expresses the SARS-COV-2 recombinant Spike protein containing the D614G mutation in a host.

### Claim 11 (depends on 9)

The vector of claim 9, wherein the vector is for use in gene therapy.

### Claim 12 (depends on 5)

A host cell comprising the nucleic acid molecule of claim 5 or a vector comprising the nucleic acid molecule.

### Claim 13 (depends on 12)

The host cell of claim 12, wherein the host cell is a prokaryotic cell or a mammalian cell.

### Claim 14 (depends on 1)

A method for expressing or producing the SARS-COV-2 recombinant Spike protein of claim 1, comprising using a nucleic acid molecule encoding the SARS-COV-2 recombinant Spike protein, a vector comprising the nucleic acid molecule, or a host cell comprising the nucleic acid molecule or the vector.

### Claim 15 (depends on 1)

A pharmaceutical composition comprising the SARS-COV-2 recombinant Spike protein of claim 1 or a nucleic acid molecule encoding the SARS-COV-2 recombinant Spike protein or a vector comprising the nucleic acid molecule and a pharmaceutically acceptable carrier and/or excipient and/or adjuvant.

### Claim 16 (depends on 15)

The pharmaceutical composition of claim 15, wherein the pharmaceutical composition is administered intradermally or intramuscularly.

### Claim 17 (depends on 15)

The pharmaceutical composition of claim 15, wherein the pharmaceutical composition is a vaccine.

### Claim 18 (depends on 15)

The pharmaceutical composition of claim 15, wherein the pharmaceutical composition is a protein vaccine comprising the SARS-COV-2 recombinant Spike protein.

### Claim 19 (depends on 15)

The pharmaceutical composition of claim 15, wherein the pharmaceutical composition is a nucleic acid vaccine comprising the nucleic acid molecule or the vector.

### Claim 20 (depends on 19)

The pharmaceutical composition of claim 19, wherein the nucleic acid vaccine is a DNA vaccine.
